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1H-NMR, IR and EI-MSAbstract 2,5-Disubstituted 1,3,4-oxadiazole compounds are one of the most attractive classes for
researchers due to their pharmacological activities. In the current research, a new series of
2-[[5-alkyl/aralkyl-1,3,4-oxadiazol-2-yl]thio]-N-[4-(4-morpholinyl)phenyl]acetamides (6a–m) were
prepared by converting different aryl/aralkyl organic acids (1a–m) successively into corresponding
esters (2a–m), hydrazides (3a–m) and 5-aryl/aralkyl-1,3,4-oxadiazol-2-thiols (4a–m). Finally, the
target compounds 6a–m were synthesized by stirring 5-aryl/aralkyl-1,3,4-oxadiazol-2-thiols
(4a–m) with 2-bromo-N-[4-(4-morpholinyl)phenyl]acetamide (5) in the presence of N,N-dimethyl-
formamide (DMF) and sodium hydride (NaH). The structures of the synthesized compounds were
elucidated through IR, 1H-NMR, 13C-NMR and mass spectral data. The compounds were also
screened for antimicrobial and hemolytic activity and most of them were found to be active against
the selected microbial species at variable extent relative to reference standards. The compounds, 6d
and 6f were active against the selected panel of microbes and the former was the most potent one.
S426 S. Gul et al.This series showed less toxicity and may be considered for further biological screening and applica-
tion trial except 6h and 6l, possessing higher cytotoxicity.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Therapeutically active and new drug constituents are needed
for the treatment of different diseases and disorders due to
increased resistance against the existing drugs, so organic chem-
ists and pharmacists are endeavoring to contribute in this ﬁeld
for new compounds with great therapeutic potential [8,17].
Heterocyclic class of organic compounds consisting of a ﬁve
membered ring containing one oxygen and two nitrogen atoms
is called Oxadiazole. Therapeutically most important and
active isomer among all the oxadiazoles is the 1,3,4-oxadiazole
ring [6]. During the last decade a variety of oxadiazole deriva-
tives were prepared and analyzed for antimicrobial and
enzyme inhibition potential [12]. Oxadiazole class of com-
pounds is known for its antitubercular, antiviral, antibacterial,
insecticidal, anticancer, anticonvulsant, anti-inﬂammatory,
and analgesic potential [15,10,18,7,20].
Six membered heterocyclic compound, morpholine and its
derivatives are important in pharmaceutics due to their great
enzyme inhibition activity and antimicrobial potential [13].
C-substituted morpholine moiety, chiral and achiral deriva-
tives of morpholine are known for their biological activity
[9]. Synthesis of new morpholine containing compounds is
the area of interest for the pharmacists because therapeutically
potent compounds are the need of hour to cure different mal-
functions and diseases [19].
2. Experimental protocol
2.1. Materials and methods
All the chemical reagents and solvents of analytical grade pur-
chased from local supplier were of Sigma Aldrich and Alfa
Aesar. By the open capillary method with the help of Grifﬁn
& George melting point apparatus, melting points were mea-
sured for all the compounds and were uncorrected. To conﬁrm
the purity of synthesized compounds, F256 20 · 20 cm, silica
coated TLC plates were utilized with n-Hexane and EtOAc
as solvent system. 1H-NMR spectra were recorded by utilizing
400 MHz Bruker spectrometers while 13C-NMR spectra were
taken at 75 and 100 MHz Bruker spectrometers, indicating
chemical shift value on ppm scale. TMS was taken as reference
standard. Jasco-320-A spectrophotometer was used to record
IR spectra by utilizing the KBr pellet method. JMS-HX-110
spectrometer was utilized for EIMS spectra.
2.2. General procedure for synthesis of different ethyl aryl/
aralkyl carboxylates (2a–m)
Aryl/aralkyl carboxylic acids (1a–m, 0.02 mol), the absolute eth-
anol (50 mL) and conc. H2SO4 (5 mL) were taken in a 250 mL
round bottom (RB) ﬂask ﬁtted with reﬂux condenser. The reac-
tionmixturewas reﬂuxed for 1.5 h. The reaction completionwas
established by thin layer chromatography (TLC).After the com-pletion, reaction mass was poured into a separating funnel con-
taining distilledwater (50 mL).Diethyl ether (15 mL)was added
to the separating funnel and mixture was neutralized by conc.
aq. sodium carbonate solution. The solution was shaken and
kept still for some time. Lower aqueous layer was discarded
and upper ether layer containing required ester was taken in a
distillation ﬂask.Diethyl etherwas distilled off and the transpar-
ent esters (2a–m) were collected from the ﬂask.
2.3. General procedure for synthesis of different aryl/aralkyl
carbohydrazides (3a–m)
Ethyl aryl/aralkyl carboxylates (2a–m, 0.018 mol) were dis-
solved in 30 mL methanol in a 100 mL RB ﬂask. 80% Hydra-
zine hydrate (0.018 mol) was added and the mixture was
stirred or reﬂuxed for 4–5 h till completion, monitored by
TLC. Excess of methanol was distilled off and cold distilled
water was added along with shaking till the appearance of
precipitates. The aryl/aralkyl carbohydrazides, 3a–m, were ﬁl-
tered, washed with distilled water and dried.
2.4. General procedure for synthesis of different 5-aryl/aralkyl-
1,3,4-oxadiazol-2-thiols (4a–m)
Aryl/aralkyl carbohydrazides (3a–m, 0.015 mol) were dissolved
in absolute ethanol (30 mL) in a 100 mLRBﬂask. Carbon disul-
ﬁde (0.015 mol) was added to the ﬂask followed by the addition
of potassium hydroxide (0.03 mol). The mixture was reﬂuxed
for 6–7 h along with proper stirring. The reaction completion
was monitored by TLC. After complete reaction, the mixture
was diluted with distilled water (30 mL) and acidiﬁed with dilute
HCl to a pH of 2. The precipitated products, 5-aryl/aralkyl-
1,3,4-oxadiazol-2-thiols 4a–m, were then ﬁltered, washed with
distilled water and re-crystallized from ethanol.
2.5. Procedure for synthesis of 2-bromo-N-[4-(4-morpholinyl)
phenyl]acetamide (5)
4-(4-Morpholinyl)benzenamine (0.1 mmol) was taken in an
iodine ﬂask (100 mL). The sodium carbonate solution was
added to maintain a pH of 9–10. Equimolar 2-bromoacetyl
bromide was introduced drop wise along with vigorous shak-
ing. The liberated gases were released by removing stopper.
After complete addition, ﬂask was set to stirring for half an
hour and monitored by TLC. The precipitates of title com-
pound were ﬁltered, washed with distilled water and dried
for further reactions.
2.6. General procedure for synthesis of 2-[(5-aryl/aralkyl-1,3,4-
oxadiazol-2-yl)thio]-N-[4-(4-morpholinyl)phenyl]acetamide
(6a–m)
5-Aryl/aralkyl-1,3,4-oxadiazol-2-thiols (4a–m, 0.001 mol) were
dissolved in 10 mL DMF in a 100 mL RB ﬂask at room
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to the reaction mixture, stirring for 0.5 h at room temperature
was done. The electrophile, 2-bromo-N-[4-(4-morpholi-
nyl)phenyl]acetamide (5), was added to reaction mixture in
an equimolar ratio and further stirred for 3–5 h. Reaction
course was monitored by TLC. After reaction completion,
the ice cold distilled water was poured into reaction contents
with shaking till the formation of precipitates. The precipitates
were ﬁltered, washed with distilled water and dried to afford
the title compounds.
2.7. Bioactivity assays
2.7.1. Microbial strains
All the synthesized compounds were tested against microor-
ganisms, including Gram-positive bacteria: Bacillus subtilis
(B. subtilis) and Staphylococcus aureus (S. aureus) and
Gram-negative bacteria: Pasteurella multocida (P. multocida)
and Escherichia coli (E. coli); and four pathogenic fungi,
Aspergillus ﬂavus (A. ﬂavus), Aspergillus niger (A. niger),
Alternaria alternate (A. alternate) and Ganoderma lucidum
(G. lucidum). All bacterial and fungal strains were obtained
from Department of Clinical Medicine and Surgery, Univer-
sity of Agriculture, Faisalabad, Pakistan. Purity and identity
of the microorganisms were veriﬁed by the Department of
Microbiology, University of Agriculture, Faisalabad, Paki-
stan. Bacterial strains were cultured at 37 C in Nutrient agar
(NA) overnight and fungal strains were cultured at 28 C using
potato dextrose agar (PDA) overnight [5].
2.7.2. Disk diffusion method
Disk diffusion method was used to ﬁnd out the antimicrobial
activity of the synthesized compounds. 100 lL suspension
of tested microorganisms was spread on PDA medium for
106 spores/mL of fungi and on NA medium for 107 colony-
forming units/mL of bacteria cells. The ﬁlter disks of 6 mm
diameter were saturated with compound solution and placed
on the agar plates inoculated with the tested microorganisms.
Filter disks without samples were employed as negative con-
trol. Fluconazole (30 lg/disk) and streptomycin (30 lg/disk)
were applied as positive reference for bacterial strains and
fungal strains, respectively. Plates were placed 4 C for 2 h
and then incubated at 37 C for 18 h for bacterial strains
and at 28 C for 24 h for fungal strains. Antimicrobial
activity was justiﬁed after comparison of diameter of growth
inhibition zone measured in mm for organisms and the con-
trols [5].
2.7.3. Hemolytic activity
Hemolytic activity was studied by the reported method [16,14].
3.0 mL fresh heparin added human blood was obtained from
voluntaries after guidance from the Department of Clinical
Medicine and Surgery, University of Agriculture, Faisalabad,
Pakistan. Plasma was disposed off after centrifuging blood at
1000g for 5 min, and blood cells were washed three times by
using cold aseptic isosmotic phosphate-buffered saline (PBS)
having pH 7.4. The RBCs for each assay were kept 108
cells per mL. 100 lL of each compound was poured in each
assay. Then the incubation of the assays was carried out at
37 C for 35 min followed by agitation after 10 min. All the
samples were kept on cold ice for 5 min and then againcentrifuged for 5 min at 1000g. 100 lL was skimmed off from
every tube and followed by 10 time dilution with cold PBS.
Two controls were employed i.e. PBS as negative control
and Triton X-100 (0.1% v/v) as positive control. The %RBCs
lysis was computed for every sample by noting the absorbance
at 576 nm using UV spectrophotometer.2.7.4. Statistical analysis
All the measurements were done in triplicate and statistical
analysis was performed by Microsoft Excel 2003. Results are
presented as mean ± sem.2.8. Spectral characterization of the synthesized compounds
2.8.1. 2-[[5-(4-Methylphenyl)-1,3,4-oxadiazol-2-yl]thio]-N-
[4-(4-morpholinyl)phenyl]acetamide (6a)
White amorphous solid; Yield: 87%; M.P. 224 C; Mol. for-
mula: C21H22N4O3S; Mol. weight: 410 gmol
1; IR (KBr, mmax/
cm1): 3038 (Ar-H stretching), 1657 (C‚O str.), 1619 (C‚N
stretching), 1476 (Ar C‚C stretching), 1237, 1063 (CAOAC
bond str.), 658 (CAS bond str.); 1H-NMR (CDCl3,
400 MHz): d/ppm 7.86 (d, J= 8.0 Hz, 2H, H-200 00 & H-600 00),
7.69 (d, J= 7.6 Hz, 2H, H-20 & H-60), 7.65 (d, J= 8.0 Hz,
2H, H-300 00 & H-500 00), 7.29 (d, J= 7.6 Hz, 2H, H-30 & H-50),
4.01 (s, 2H, H-2), 3.96 (br. s, 2H, He-2
00 & He-600), 3.85 (t,
J= 4.4 Hz, 2H, Ha-2
00 & Ha-600), 3.42 (br. s, 2H, He-300 &
He-5
00), 3.00 (t, J= 4.4 Hz, 2H, Ha-300 & Ha-500), 2.41 (s, 3H,
CH3-4
00 00); 13C-NMR (CDCl3, 100 MHz): d/ppm 169.4 (C-1),
166.3 (C-2000), 164.9 (C-5000), 142.7 (C-40), 140.7 (C-400 00), 129.7
(C-200 00 & C-600 00), 126.5 (C-300 00 & C-500 00), 121.0 (C-20 & C-60),
119.9 (C-10), 116.5 (C-100 00), 111.4 (C-30 & C-50), 66.3 (C-200 &
C-600), 48.7 (C-300 & C-500), 36.3 (C-2), 21.4 (CH3-400 00); EIMS
(m/z): 410 [M]+, 277 [C13H15N3O2S]
+, 251 [C12H15N2O2S]
+,
205 [C11H13N2O2]
+, 192 [M-C12H14N2O2]
+, 177 [M-
C10H13N2O]
+, 162 [C10H12NO]
+, 119 [M-C13H15N4O2S]
+,
117 [M-C13H15N3O3S]
+, 91 [M-C14H15N4O3S]
+, 86
[C4H8NO]
+.2.8.2. 2-[[5-(2-Chlorophenyl)-1,3,4-oxadiazol-2-yl]thio]-N-
[4-(4-morpholinyl)phenyl] acetamide (6b)
White amorphous solid; Yield: 81%; M.P. 180 C; Mol. for-
mula: C20H19ClN4SO3; Mol. weight: 430.5 gmol
1; IR (KBr,
mmax/cm
1): 3036 (Ar-H stretching), 1655 (C‚O str.), 1617
(C‚N stretching), 1474 (Ar C‚C stretching), 1236, 1061
(CAOAC bond str.), 656 (CAS bond str.); 1H-NMR (CDCl3,
400 MHz): d/ppm 7.90 (d, J= 7.6 Hz, 1H, H-600 00), 7.78 (d,
J= 8.0 Hz, 1H, H-300 00), 7.76 (d, J= 8.0 Hz, 2H, H-20 & H-
60), 7.54 (d, J= 8.0 Hz, 2H, H-30 & H-50), 7.48 (t,
J= 7.6 Hz, 1H, H-500 00), 7.40 (t, J= 7.6 Hz, 1H, H-400 00), 4.06
(s, 2H, H-2), 4.04–3.96 (m, 4H, H-200 & H-600), 3.48 (br. s,
2H, He-3
00 & He-500), 3.27 (br. s, 2H, Ha-300 & Ha-500);
13C-
NMR (CDCl3, 100 MHz): d/ppm 169.5 (C-1), 167.3 (C-5000),
166.2 (C-2000), 147.3 (C-40), 133.6 (C-10),131.2 (C-400 00), 131.0
(C-200 00), 129.1 (C-300 00), 127.8 (C-600 00), 127.0 (C-500 00), 126.7 (C-
100 00), 119.7 (C-20 & C-60), 111.6 (C-30 & C-50), 66.4 (C-200 &
C-600), 47.2 (C-300 & C-500), 33.2 (C-2); EIMS (m/z): 430
[M]+, 277 [C13H15N3O2S]
+, 251 [C12H15N2O2S]
+, 212 [M-
C12H14N2O2]
+, 205 [C11H13N2O2]
+, 177 [M-C10H13N2O]
+,
162 [C10H12NO]
+, 139 [M-C13H15N4O2S]
+, 137 [M-C13H15-
N3O3S]
+, 111 [M-C14H15N4O3S]
+, 86 [C4H8NO]
+.
S428 S. Gul et al.2.8.3. 2-[[5-(3-Chlorophenyl)-1,3,4-oxadiazol-2-yl]thio]-N-
[4-(4-morpholinyl)phenyl] acetamide (6c)
Off white amorphous solid; Yield: 76%; M.P. 226 C; Mol.
formula: C20H19ClN4SO3; Mol. weight: 430.5 gmol
1; IR
(KBr, mmax/cm
1): 3030 (Ar-H stretching), 1649 (C‚O str.),
1611 (C‚N stretching), 1468 (Ar C‚C stretching), 1229,
1055 (CAOAC bond str.), 650 (CAS bond str.); 1H-NMR
(CDCl3, 400 MHz): d/ppm 7.87 (d, J= 7.6 Hz, 1H, H-600 00),
7.80 (s, 1H, H-200 00), 7.51 (d, J= 7.2 Hz, 1H, H-400 00), 7.45 (t,
J= 7.6 Hz, 1H, H-500 00), 7.40 (d, J= 8.4 Hz, 2H, H-20 & H-
60), 6.71 (d, J= 8.4 Hz, 2H, H-30 & H-50), 4.05 (s, 2H, H-2),
4.02–3.94 (m, 4H, H-200 & H-600), 3.48 (br. s, 2H, He-300 &
He-5
00), 3.26 (br. s, 2H, Ha-300 & Ha-500);
13C-NMR (CDCl3,
100 MHz): d/ppm 169.3 (C-1), 166.2 (C-2000), 165.8 (C-5000),
147.6 (C-40), 134.6 (C-300 00), 133.3 (C-10), 130.7 (C-100 00), 130.5
(C-200 00), 128.5 (C-400 00), 127.4 (C-600 00), 127.4 (C-500 00), 119.5
(C-20 & C-60), 111.6 (C-30 & C-50), 66.8 (C-200 & C-600), 47.3
(C-300 & C-500), 33.2 (C-2); EIMS (m/z): 430 [M]+, 277 [C13H15-
N3O2S]
+, 251 [C12H15N2O2S]
+, 212 [M-C12H14N2O2]
+, 205
[C11H13N2O2]
+, 177 [M-C10H13N2O]
+, 162 [C10H12NO]
+,
139 [M-C13H15N4O2S]
+, 137 [M-C13H15N3O3S]
+, 111 [M-
C14H15N4O3S]
+, 86 [C4H8NO]
+.
2.8.4. 2-[[5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-yl]thio]-N-
[4-(4-morpholinyl)phenyl] acetamide (6d)
Off white amorphous solid; Yield: 72%; M.P. 238 C; Mol.
formula: C20H19ClN4SO3; Mol. weight: 430.5 gmol
1; IR
(KBr, mmax/cm
1): 3027 (Ar-H stretching), 1647 (C‚O str.),
1609 (C‚N stretching), 1466 (Ar C‚C stretching), 1227,
1053 (CAOAC bond str.), 647 (CAS bond str.); 1H-NMR
(CDCl3, 400 MHz): d/ppm 7.91 (d, J= 8.4 Hz, 2H, H-200 00 &
H-600 00), 7.47 (d, J= 8.4 Hz, 2H, H-300 00 & H-500 00), 7.36 (d,
J= 9.2 Hz, 2H, H-20 & H-60), 6.95 (d, J= 9.2 Hz, 2H, H-30
& H-50), 3.99 (s, 2H, H-2), 3.98 (br. s, 2H, He-200 & He-600),
3.83 (t, J= 4.4 Hz, 2H, Ha-2
00 & Ha-600), 3.14 (br. s, 2H, He-
300 & He-500), 2.98 (t, J= 4.4 Hz, 2H, Ha-300 & Ha-500);
13C-
NMR (CDCl3, 100 MHz): d/ppm 169.6 (C-1), 166.1 (C-2000),
164.7 (C-5000), 147.5 (C-40), 137.7 (C-400 00), 133.6 (C-10), 129.8
(C-300 00 & C-500 00), 129.6 (C-100 00), 129.0 (C-200 00 & C-600 00), 119.7
(C-20 & C-60), 111.8 (C-30 & C-50), 66.9 (C-200 & C-600), 47.2
(C-300 & C-500), 33.5 (C-2); EIMS (m/z): 430 [M]+, 277 [C13H15-
N3O2S]
+, 251 [C12H15N2O2S]
+, 212 [M-C12H14N2O2]
+, 205
[C11H13N2O2]
+, 177 [M-C10H13N2O]
+, 162 [C10H12NO]
+,
139 [M-C13H15N4O2S]
+, 137 [M-C13H15N3O3S]
+, 111 [M-
C14H15N4O3S]
+, 86 [C4H8NO]
+.
2.8.5. 2-[[5-(3-Nitrophenyl)-1,3,4-oxadiazol-2-yl]thio]-N-[4-
(4-morpholinyl)phenyl]acetamide (6e)
Off white amorphous solid; Yield: 78%; M.P. 210 C; Mol.
formula: C20H19N5O5S; Mol. weight: 441 gmol
1; IR (KBr,
mmax/cm
1): 3025 (Ar-H stretching), 1645 (C‚O str.), 1607
(C‚N stretching), 1464 (Ar C‚C stretching), 1225, 1051
(CAOAC bond str.), 645 (CAS bond str.); 1H-NMR (CDCl3,
400 MHz): d/ppm 9.47 (s, 1H, H-200 00), 8.39 (d, J= 8.4 Hz, 1H,
H-600 00), 8.33 (d, J= 7.6 Hz, 1H, H-400 00), 7.73 (t, J= 8.0 Hz,
1H, H-500 00), 7.39 (d, J= 8.4 Hz, 2H, H-20 & H-60), 6.71 (d,
J= 8.4 Hz, 2H, H-30 & H-50), 4.11 (s, 2H, H-2), 4.07–4.01
(m, 4H, H-200 & H-600), 3.49–3.37 (m, 4H, H-300 & H-500); 13C-
NMR (CDCl3, 100 MHz): d/ppm 168.5 (C-1), 167.4 (C-5000),
166.2 (C-2000), 148.6 (C-300 00), 147.3 (C-40), 135.6 (C-600 00), 133.6
(C-10), 132.6 (C-100 00), 131.6 (C-500 00), 125.2 (C-400 00), 121.4(C-200 00), 119.7 (C-20 & C-60), 110.6 (C-30 & C-50), 66.4 (C-200
& C-600), 47.4 (C-300 & C-500), 33.2 (C-2); EIMS (m/z): 441
[M]+, 277 [C13H15N3O2S]
+, 251 [C12H15N2O2S]
+, 223 [M-
C12H14N2O2]
+, 205 [C11H13N2O2]
+, 177 [M-C10H13N2O]
+,
162 [C10H12NO]
+, 150 [M-C13H15N4O2S]
+, 148 [M-C13H15-
N3O3S]
+, 122 [M-C14H15N4O3S]
+, 86 [C4H8NO]
+.
2.8.6. 2-[[5-(3-Aminophenyl)-1,3,4-oxadiazol-2-yl]thio]-N-[4-
(4-morpholinyl)phenyl]acetamide (6f)
White amorphous solid; Yield: 71%; M.P. 223 C; Mol. for-
mula: C20H21N5O3S; Mol. weight: 411 gmol
1; IR (KBr, mmax/
cm1): 3029 (Ar-H stretching), 1643 (C‚O str.), 1615 (C‚N
stretching), 1467 (Ar C‚C stretching), 1224, 1051 (CAOAC
bond str.), 651 (CAS bond str.); 1H-NMR (CDCl3,
400 MHz): d/ppm 7.97 (d, J= 8.0 Hz, 2H, H-20 & H-60),
7.76 (s, 1H, H-200 00), 7.72 (d, J= 8.8 Hz, 1H, H-600 00), 7.53 (t,
J= 7.2 Hz, 1H, H-500 00), 7.50 (d, J= 7.6 Hz, 2H, H-30 & H-
50), 7.37 (d, J= 7.2 Hz, 1H, H-400 00), 4.03 (s, 2H, H-2), 3.98
(br. s, 2H, He-2
00 & He-600), 3.91 (br. s, 2H, Ha-200 & Ha-600),
3.46 (br. s, 2H, He-3
00 & He-500), 3.10 (br. s, 2H, Ha-300 & Ha-
500); 13C-NMR (CDCl3, 100 MHz): d/ppm 169.6 (C-1), 167.5
(C-5000), 166.3 (C-2000), 147.4 (C-40), 146.7 (C-300 00), 133.5 (C-10),
132.1 (C-500 00), 129.5 (C-100 00), 123.7 (C-600 00), 119.8 (C-20 &
C-60), 117.5 (C-400 00), 116.3 (C-200 00), 111.5 (C-30 & C-50), 66.5
(C-200 & C-600), 47.3 (C-300 & C-500), 33.3 (C-2); EIMS (m/z):
411 [M]+, 277 [C13H15N3O2S]
+, 251 [C12H15N2O2S]
+, 205
[C11H13N2O2]
+, 193 [M-C12H14N2O2]
+, 177 [M-
C10H13N2O]
+, 162 [C10H12NO]
+, 120 [M-C13H15N4O2S]
+,
118 [M-C13H15N3O3S]
+, 92 [M-C14H15N4O3S]
+, 86
[C4H8NO]
+.
2.8.7. 2-[[5-(4-Aminophenyl)-1,3,4-oxadiazol-2-yl]thio]-N-[4-
(4-morpholinyl)phenyl]acetamide (6g)
White amorphous solid; Yield: 71%; M.P. 223 C; Mol. for-
mula: C20H21N5O3S; Mol. weight: 411 gmol
1; IR (KBr, mmax/
cm1): 3032 (Ar-H stretching), 1646 (C‚O str.), 1618 (C‚N
stretching), 1470 (Ar C‚C stretching), 1227, 1054 (CAOAC
bond str.), 654 (CAS bond str.); 1H-NMR (CDCl3,
400 MHz): d/ppm 7.94 (d, J= 8.0 Hz, 2H, H-200 00 & H-600 00),
7.88 (d, J= 8.8 Hz, 2H, H-20 & H-60), 7.79 (d, J= 8.0 Hz,
2H, H-300 00 & H-500 00), 7.71 (d, J= 8.8 Hz, 2H, H-30 & H-50),
4.11 (s, 2H, H-2), 4.02–3.91 (m, 4H, H-200 & H-600), 3.55–3.41
(m, 4H, H-300 & H-500); 13C-NMR (CDCl3, 100 MHz): d/ppm
169.6 (C-1), 166.1 (C-2000), 164.7 (C-5000), 153.1 (C-400 00), 147.7
(C-40), 133.4 (C-10), 125.6 (C-200 00 & C-600 00), 125.3 (C-100 00),
119.5 (C-20 & C-60), 114.1 (C-300 00 & C-500 00), 111.2 (C-30 & C-
50), 66.1 (C-200 & C-600), 46.9 (C-300 & C-500), 32.9 (C-2); EIMS
(m/z): 411 [M]+, 277 [C13H15N3O2S]
+, 251 [C12H15N2O2S]
+,
205 [C11H13N2O2]
+, 193 [M-C12H14N2O2]
+, 177 [M-
C10H13N2O]
+, 162 [C10H12NO]
+, 120 [M-C13H15N4O2S]
+,
118 [M-C13H15N3O3S]
+, 92 [M-C14H15N4O3S]
+, 86
[C4H8NO]
+.
2.8.8. 2-[[5-[(4-Chlorophenoxy)methyl]-1,3,4-oxadiazol-2-
yl]thio]-N-[4-(4-morpholinyl)phenyl ]acetamide (6h)
White amorphous solid; Yield: 68%; M.P. 212 C; Mol. for-
mula: C21H21N4O4S; Mol. weight: 425 gmol
1; IR (KBr, mmax/
cm1): 3037 (Ar-H stretching), 1651 (C‚O str.), 1623 (C‚N
stretching), 1475 (Ar C‚C stretching), 1232, 1059 (CAOAC
bond str.), 659 (CAS bond str.); 1H-NMR (CDCl3,
400 MHz): d/ppm 7.61 (d, J= 8.8 Hz, 2H, H-20 & H-60),
Synthesis of 2-bromo-N-[4-(4-morpholinyl)phenyl]acetamide derivatives S4297.26 (d, J= 8.4 Hz, 2H, H-300 00 & H-500 00), 6.97 (d, J= 8.4 Hz,
2H, H-200 00 & H-600 00), 6.90 (d, J= 8.8 Hz, 2H, H-30 & H-50),
5.19 (s, 2H, H-700 00), 3.99 (s, 2H, H-2), 3.94 (br. s, 2H, He-200
& He-6
00), 3.83 (t, J= 4.4 Hz, 2H, Ha-200 & Ha-600), 3.32 (br.
s, 2H, He-3
00 & He-500), 2.98 (t, J= 4.4 Hz, 2H, Ha-300 & Ha-
500); 13C-NMR (CDCl3, 100 MHz): d/ppm 166.0 (C-1), 164.7
(C-2000), 164.5 (C-5000), 155.7 (C-100 00), 147.1 (C-40), 143.2
(C-400 00), 133.2 (C-10), 129.4 (C-300 00 & C-500 00), 121.0 (C-20 & C-
60), 116.0 (C-200 00 & C-600 00), 110.8 (C-30 & C-50), 65.6 (C-700 00),
59.7 (C-200 & C-600), 49.2 (C-300 & C-500), 36.4 (C-2); EIMS
(m/z): 460 [M]+, 277 [C13H15N3O2S]
+, 251 [C12H15N2O2S]
+,
242 [M-C12H14N2O2]
+, 205 [C11H13N2O2]
+, 177 [M-
C10H13N2O]
+, 169 [M-C13H15N4O2S]
+, 167 [M-C13H15N3O3-
S]+,162 [C10H12NO]
+, 141 [M-C14H15N4O3S]
+, 111 [C14H15-
N4O3S]
+, 86 [C4H8NO]
+.2.8.9. 2-[[5-(1,3-Benzodioxol-5-yl)-1,3,4-oxadiazol-2-yl]thio]-
N-[4-(4-morpholinyl)phenyl] acetamide (6i)
White amorphous solid; Yield: 68%; M.P. 212 C; Mol. for-
mula: C21H20N4O5S; Mol. weight: 440 gmol
1; IR (KBr, mmax/
cm1): 3035 (Ar-H stretching), 1649 (C‚O str.), 1613 (C‚N
stretching), 1477 (Ar C‚C stretching), 1224, 1059 (CAOAC
bond str.), 651 (CAS bond str.); 1H-NMR (CDCl3,
400 MHz): d/ppm 7.65 (d, J= 2.4 Hz, 1H, H-200 00), 7.51 (d,
J= 8.4 Hz, 2H, H-20 & H-60), 7.36 (dd, J= 8.4, 2.4 Hz, 1H,
H-600 00), 6.95 (d, J= 8.4 Hz, 1H, H-500 00), 6.89 (d, J= 8.0 Hz,
2H, H-30 & H-50), 6.05 (s, 2H, H-700 00), 3.98 (s, 2H, H-2), 3.95
(br. s, 2H, He-2
00 & He-600), 3.84 (t, J= 4.4 Hz, 2H, Ha-200 &
Ha-6
00), 3.27 (br. s, 2H, He-300 & He-500), 2.98 (t, J= 4.4 Hz,
2H, Ha-3
00 & Ha-500);
13C-NMR (CDCl3, 100 MHz): d/ppm
165.8 (C-1), 164.9 (C-2000), 163.8 (C-5000), 150.8 (C-300 00), 148.2
(C-400 00), 147.3 (C-40), 133.6 (C-10), 122.8 (C-100 00), 121.8 (C-
600 00), 121.0 (C-20 & C-60), 116.4 (C-30 & C-50), 108.7 (C-500 00),
106.4 (C-200 00), 101.8 (C-700 00), 66.5 (C-200 & C-600), 49.3 (C-300
& C-500), 36.3 (C-2); EIMS (m/z): 440 [M]+, 277 [C13H15N3O2-
S]+, 251 [C12H15N2O2S]
+, 222 [M-C12H14N2O2]
+,205
[C11H13N2O2]
+, 177 [M-C10H13N2O]
+, 162 [C10H12NO]
+,
149 [M-C13H15N4O2S]
+, 147 [M-C13H15N3O3S]
+, 121 [M-
C14H15N4O3S]
+, 86 [C4H8NO]
+.2.8.10. 2-[[5-(Phenylmethyl)-1,3,4-oxadiazol-2-yl]thio]-N-[4-
(4-morpholinyl)phenyl]acetamide (6j)
White amorphous solid; Yield: 65%; M.P. 168 C; Mol. for-
mula: C21H22N3O3S; Mol. weight: 396 gmol
1; IR (KBr, mmax/
cm1): 3038 (Ar-H stretching), 1652 (C‚O str.), 1624 (C‚N
stretching), 1476 (Ar C‚C stretching), 1233, 1060 (CAOAC
bond str.), 660 (CAS bond str.); 1H-NMR (CDCl3,
400 MHz): d/ppm 7.59 (d, J= 8.0 Hz, 2H, H-20 & H-60),
7.33–7.27 (m, 5H, H-200 00 to H-600 00), 6.95 (d, J= 8.0 Hz, 2H,
H-30 & H-50), 4.16 (s, 2H, H-700 00), 3.94 (s, 2H, H-2), 3.88 (br.
s, 2H, He-2
00 & He-600), 3.84 (t, J= 4.4 Hz, 2H, Ha-200 & Ha-
600), 3.34 (br. s, 2H, He-300 & He-500), 2.99 (t, J= 4.4 Hz, 2H,
Ha-3
00 & Ha-500);
13C-NMR (CDCl3, 100 MHz): d/ppm 166.9
(C-1), 165.0 (C-2000), 164.8 (C-5000), 132.9 (C-40), 129.0 (C-100 00),
128.8 (C-10), 128.6 (C-300 00 & C-500 00), 128.5 (C-200 00 & C-600 00),
127.6 (C-400 00), 121.0 (C-20 & C-60), 116.6 (C-30 & C-50), 66.4
(C-200 & C-600), 49.3 (C-300 & C-500), 36.2 (C-2), 31.5 (C-700 00);
EIMS (m/z): 410 [M]+, 277 [C13H15N3O2S]
+, 251 [C12H15N2-
O2S]
+, 205 [C11H13N2O2]
+, 192 [M-C12H14N2O2]
+, 177 [M-
C10H13N2O]
+, 162 [C10H12NO]
+, 119 [M-C13H15N4O2S]
+,117 [M-C13H15N3O3S]
+, 91 [M-C14H15N4O3S]
+, 86
[C4H8NO]
+.
2.8.11. 2-[[5-[1-(Phenylsulfonyl)-4-piperidinyl]-1,3,4-
oxadiazol-2-yl]thio]-N-[4-(4-morpholinyl)phenyl]acetamide
(6k)
White amorphous solid; Yield: 71%; M.P. 220 C; Mol.
formula: C25H24N4O5S2; Mol. weight: 492 gmol
1; IR (KBr,
mmax/cm
1): 3035 (Ar-H stretching), 1647 (C‚O str.), 1617
(C‚N stretching), 1474 (Ar C‚C stretching), 1221, 1057
(CAOAC bond str.), 657 (CAS bond str.); 1H-NMR (CDCl3,
400 MHz): d/ppm 7.75 (d, J= 7.2 Hz, 2H, H-20 & H-60), 7.61–
7.54 (m, 5H, H-200 00 0 to H-600 00 0), 6.97 (d, J= 7.2 Hz, 2H, H-30 &
H-50), 4.23 (s, 2H, H-2), 3.94 (br. s, 2H, He-200 & He-600), 3.78–
3.76 (m, 4H, H-200 00 & H-600 00), 3.63 (br. s, 2H, Ha-200 & Ha-600),
2.86 (br. s, 2H, He-3
00 & He-500), 2.54 (br. s, 2H, Ha-300 & Ha-500),
2.13–2.08 (m, 1H, H-400 00), 1.98–1.95 (m, 4H, H-300 00 & H-500 00);
13C-NMR (CDCl3 & CD3OD, 100 MHz): d/ppm 170.0 (C-
5000), 169.8 (C-1), 168.4 (C-2000), 147.2 (C-40), 145.7 (C-100 00 0),
133.9 (C-10), 133.2 (C-400 00 0), 129.3 (C-300 00 0 & 500 00 0), 127.0 (C-
200 00 0 & 600 00 0), 118.9 (C-20 & C-60), 110.8 (C-30 & C-50), 65.9
(C-200 & C-600), 48.9 (C-300 & C-500), 42.9 (C-200 00 & C-600 00),
33.3 (C-2), 32.9 (C-400 00), 29.0 (C-300 00 & C-500 00); EIMS (m/z):
543 [M]+, 325 [M-C12H14N2O2]
+, 277 [C13H15N3O2S]
+,
252 [M-C13H15N4O2S]
+, 251 [C12H15N2O2S]
+, 250 [M-C13-
H15N3O3S]
+, 224 [M-C14H15N4O3S]
+, 205 [C11H13N2O2]
+,
177 [M-C10H13N2O]
+, 162 [C10H12NO]
+, 141 [M-C19H24N5-
O3S]
+, 77 [M-C19H24N5O5S2]
+, 86 [C4H8NO]
+.
2.8.12. 2-[[5-[2-(1,3-Benzodioxol-5-yl)ethenyl]-1,3,4-
oxadiazol-2-yl]thio]-N-[4-(4-morpholinyl)phenyl]acetamide
(6l)
Off white amorphous solid; Yield: 73%; M.P. 222 C; Mol.
formula: C23H22N4O5S; Mol. weight: 466 gmol
1; IR (KBr,
mmax/cm
1): 3034 (Ar-H stretching), 1648 (C‚O str.), 1620
(C‚N stretching), 1472 (Ar C‚C stretching), 1229, 1056
(CAOAC bond str.), 656 (CAS bond str.); 1H-NMR (CDCl3,
400 MHz): d/ppm 7.36 (d, J= 8.0 Hz, 2H, H-20 & H-60), 7.03
(d, J= 1.2 Hz, 1H, H-200 00), 6.98 (dd, J= 8.0, 1.6 Hz, 1H, H-
600 00), 6.91 (d, J= 8.0 Hz, 1H, H-500 00), 6.81 (d, J= 8.0 Hz, 2H,
H-30 & H-50), 6.01 (s, 2H, H-700 00), 3.99 (s, 2H, H-2), 3.95 (br. s,
2H, He-2
00 & He-600), 3.86 (t, J= 4.4 Hz, 2H, Ha-200 & Ha-600),
3.43 (br. s, 2H, He-3
00 & He-500), 3.01 (t, J= 4.4 Hz, 2H, Ha-300
& Ha-5
00); 13C-NMR (CDCl3, 100 MHz): d/ppm 168.9 (C-1),
165.1 (C-2000), 163.5 (C-5000), 149.4 (C-400 00), 148.9 (C-300 00),
147.8 (C-40), 141.7 (C-800 00), 132.9 (C-10), 131.5 (C-100 00), 121.0
(C-900 00), 120.5 (C-600 00), 120.1 (C-20 & C-60), 110.6 (C-30 &
C-50), 107.8 (C-500 00), 106.8 (C-200 00), 101.0 (C-700 00), 65.9 (C-200
& C-600), 46.9 (C-300 & C-500), 32.6 (C-2); EIMS (m/z): 466
[M]+, 277 [C13H15N3O2S]
+, 251 [C12H15N2O2S]
+, 248 [M-
C12H14N2O2]
+, 205 [C11H13N2O2]
+, 177 [M-C10H13N2O]
+,
175 [M-C13H15N4O2S]
+, 173 [M-C13H15N3O3S]
+, 162 [C10-
H12NO]
+, 147 [M-C14H15N4O3S]
+, 121 [M-C16H17N4O3S]
+,
91 [M-C17H19N4O4S]
+, 86 [C4H8NO]
+.
2.8.13. 2-[[5-(2-Naphthylmethyl)-1,3,4-oxadiazol-2-yl]thio]-
N-[4-(4-morpholinyl)phenyl] acetamide (6m)
Off white amorphous solid; Yield: 77%; M.P. 209 C; Mol.
formula: C25H24N4O3S; Mol. weight: 460 gmol
1; IR (KBr,
mmax/cm
1): 3035 (Ar-H stretching), 1649 (C‚O str.), 1621
(C‚N stretching), 1473 (Ar C‚C stretching), 1230, 1057
S430 S. Gul et al.(CAOAC bond str.), 657 (CAS bond str.); 1H-NMR (CDCl3,
400 MHz): d/ppm 9.18 (s, 1H, H-100 00), 8.05 (d, J= 8.0 Hz, 1H,
H-400 00), 7.86 (d, J= 7.6 Hz, 1H, H-800 00), 7.82 (t, J= 4.4 Hz,
1H, H-500 00), 7.55 (d, J= 8.0 Hz, 1H, H-300 00), 7.53–7.49 (m,
2H, H-600 00 & H-700 00), 7.44 (d, J= 8.0 Hz, 2H, H-20 & H-60),
6.97 (d, J= 8.0 Hz, 2H, H-30 & H-50), 4.61 (s, 2H, H-1100 00),
3.93 (s, 2H, H-2), 3.87–3.83 (m, 4H, H-200 & H-600), 3.23–3.16
(m, 4H, H-300 & H-500); 13C-NMR (CDCl3, 100 MHz): d/ppm
167.9 (C-1), 167.2 (C-2000), 166.1 (C-5000), 146.9 (C-40), 133.8
(C-10), 133.1 (C-1000 00), 130.5 (C-200 00), 130.0 (C-800 00), 129.6 (C-
900 00), 129.4 (C-500 00), 128.6 (C-400 00), 127.3 (C-700 00), 125.8 (C-
600 00), 125.4 (C-300 00), 125.1 (C-100 00), 118.8 (C-20 & C-60), 112.1
(C-30 & C-50), 67.2 (C-200 & C-600), 47.8 (C-300 & C-500), 33.1
(C-2), 32.8 (C-1100 00); EIMS (m/z): 460 [M]+, 277 [C13H15N3-
O2S]
+, 251 [C12H15N2O2S]
+, 242 [M-C12H14N2O2]
+, 205
[C11H13N2O2]
+, 177 [M-C10H13N2O]
+, 169 [M-C13H15N4O2-
S]+, 167 [M-C13H15N3O3S]
+,162 [C10H12NO]
+, 141 [M-C14-
H15N4O3S]
+, 86 [C4H8NO]
+.
3. Results and discussion
The 2-[[5-aryl/aralkyl-1,3,4-oxadiazol-2-yl]thio]-N-[4-(4-mor-
pholinyl)phenyl]acetamides, 6a–m, were competently synthe-
sized according to the protocol sketch in Scheme 1 and
different substituted aryl/aralkyl groups are mentioned in
Table 1. The general reaction procedures along with necessary
conditions and the spectral characterization are described in
the experimental section. In continuation of our previous
work [1–3,4,11], the synthesis and biological screening of
new 2-[[5-alkyl/aralkyl-1,3,4-oxadiazol-2-yl]thio]-N-[4-(4-mor-
pholinyl)phenyl]acetamide compounds were performed with
an objective to detect the anti-microbial and hemolytic activity
of the synthesized compounds. All the synthesized derivatives
were screened for anti-microbial and cytotoxic potential andBr
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Scheme 1 Outline for the synthesis of 2-[(5-aryl/aralkyl-1,3,4-oxadiaz
conditions: (I) Ethanol, Conc. H2SO4, reﬂux for 6–8 h. (II) Hydrazin
Reﬂux for 6–7 h. (IV) 2-Bromoacetyl bromide, Aq. Na2CO3 soln., stirfound that most of the compounds exhibited signiﬁcant activ-
ity against the selected microbial species relative to reference
standard drugs.
3.1. Chemistry
In the present research, the compounds, 6a–m, were synthe-
sized in a series of steps. The different aryl/aralkyl organic
acids were subjected to reﬂux with ethanol in the presence of
concentrated H2SO4 to yield corresponding ethyl esters. Car-
bohydrazides were synthesized from corresponding esters by
reacting with hydrated hydrazine in methanol. 5-Aryl/aral-
kyl-1,3,4-oxadiazol-2-thiols, 4a–m, were prepared by intermo-
lecular cyclization of different aryl/aralkyl carbohydrazides
with carbon disulﬁde in the presence of potassium hydroxide
in ethanol, as solvent. The target compounds were synthesized
by electrophilic substitution reaction of 5-aryl/aralkyl-1,3,4-
oxadiazol-2-thiols, 4a–m, with 2-bromo-N-[4-(4-morpholi-
nyl)phenyl] acetamide (5). The structural elucidation of all
the synthesized compounds was brought about by IR, EIMS,
1H-NMR and 13C-NMR and screened them for biological
activities. For compound, 6a, the IR spectra showed the pres-
ence of aromatic C-H stretching at 3038 cm1, C‚N stretch-
ing at 1619 cm1, C‚C stretching at 1476 cm1 while C-O-C
stretching appeared at 1237 and 1063 cm1. In 1H-NMR, for
the morpholine ring, the most deshielded equatorial proton
of position-2 and position-6, due to adjacent electronegative
oxygen, appeared around d 3.96 as broad singlet integrated
for two protons while axial protons of position-2 and pos-
tion-6 appeared around d 3.85 as triplet with coupling constant
4.4 Hz with integration of two protons. Similarly equatorial
protons of 3rd and 5th position, adjacent to nitrogen atom,
revealed around d 3.42 as broad singlet having integration of
two protons while axial protons resonated around d 3.00 asN
O
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Table 1 Different 5-substituted aryl/aralkyl groups of 1,3,4-oxadiazole moiety.
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Figure 1 The mass fragmentation pattern of 2-[[5-[(4-chlorophenoxy)methyl]-1,3,4-oxadiazol-2-yl]thio]-N-[4-(4-morpholi-
nyl)phenyl]acetamide (6h).
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Table 3 Antifungal activity of synthesized compounds.
C. No. Zone of inhibition (mm)
A. niger A. ﬂavus G. lucidum A. alternata
6a – – – –
6b – – – –
6c 22 20 19 21
6d 25 24 22 22
6e 18 22 20 22
6f 23 26 22 22
6g – – –
6h – – – –
6i – – – –
6j 18 20 18 15
6k 24 23 13 16
6l – – – –
6m – – – –
Fluconazole 25 26 25 26
Table 2 Antibacterial activity of synthesized compounds.
C. No. Zone of inhibition (mm)
S. aureus B. subtilis P. multocida E. coli
6a 19 18 – –
6b 17 20 – –
6c 20 20 21 22
6d 25 25 23 24
6e 20 21 21 23
6f 24 25 21 23
6g – – –
6h – – – –
6i – – – –
6j 20 21 15 16
6k – – – –
6l – – – –
6m – – – –
Streptomycin 27 28 24 25
S432 S. Gul et al.triplet having J-coupling 4.4 Hz with integration of two
protons. Signals of the N-substituted p-amino phenyl ring
attached to the morpholine ring appeared as two doublets
around d 7.69 and 7.29 with coupling constant 7.6 Hz and each
integrated for two protons. Methylene of acetamide linkage
appeared as singlet around d 4.01 ppm integrated for two
protons, due to deshielding effect of neighboring sulfur atom
and electron withdrawing effect of the carbonyl group. The
four protons of the p-substituted phenyl ring attached to
1,3,4-oxadiazole moiety showed characteristic two doublets
(J-coupling of 8.0 Hz) with double integration at d 7.86 for
two protons adjacent to the 1,3,4-Oxadiazole ring and at d
7.65 for two protons in vicinity of the methyl group. The sin-
glet of three protons of the methyl group resonated at d 2.41.
In 13C-NMR, quaternary carbons of the Oxadiazole ring
appeared at d 166.3 (C-2000) and 164.9 (C-5000); that of acetamide
linkage appeared at d 169.4 (C-1); that of the phenyl ring adja-
cent to the morpholine ring resonated at d 142.7 (C-40) and
119.9 (C-10); and that of the phenyl ring linked to Oxadiazole
moiety resonated at d 140.7 (C-400 00) and 116.5 (C-100 00). The
methine carbon signals with double intensity appeared for
both phenyl rings at d 129.7 (C-200 00 & C-600 00), 126.5 (C-300 00 &
C-500 00), 121.0 (C-20 & C-60) and 111.4 (C-30 & C-50). The meth-
ylene carbons of the morpholine ring resonated at d 63.3 (due
to vicinal oxygen) and 48.7 (due to vicinal nitrogen); and that
of the acetamoyl group at d 36.5 (due to neighboring carbonyl
group and sulfur atom). The only methyl carbon revealed sig-
nal at d 21.4. In EIMS molecular ion peak appeared at m/z
410. Other characteristic peaks appeared at m/z 277, 251,
205, 177, 162 and 86. The characteristic peak at m/z 177 corre-
sponds to p-aminophenyl substituted morpholine moiety while
m/z 162 corresponds to phenyl substituted morpholine while
m/z 86 is related to morpholine cation. The mass fragmenta-
tion pattern of the 2-[[5-[(4-chlorophenoxy)methyl]-1,3,4-oxa-
diazol-2-yl]thio]-N-[4-(4-morpholinyl)phenyl]acetamide (6h) is
sketched in Fig. 1. All this spectroscopic analysis helped to
elucidate the structure of 6a and all the other synthesized
compounds.
3.2. Biological activities
All the synthesized compounds were analyzed for antibacterial
activity against two gram positive bacteria (S. aureus, B. subtil-
is) and two gram negative bacteria (P. multocida and E. coli);
antifungal activity (A. niger, A. ﬂavus, G. lucidum and A. alter-
nata) and hemolytic activity. In antibacterial and antifungal
activities, zone of inhibition for all the compounds was calcu-
lated in millimeter (mm) (Table 2 and 3) and for hemolytic
activity%age lysis was calculated.
3.2.1. Antibacterial activity
Compound 6d showed better inhibition against all the bacte-
rial strains relative to reference standard, streptomycin, while
compound 6f exhibited better results against three bacterial
strains, S. aureus, B. subtilis and E. coli with zones of inhibi-
tion as 24, 25, and 23 mm respectively relative to reference.
Compound 6e was found to be active against only one gram
negative bacterial strain with zone of inhibition as 23 mm.
Compounds, 6c and 6j were also active against all the bacterial
strains but not with appreciable values. Compounds, 6a and 6b
were active against only two gram positive bacterial strains S.aureus and B. subtilis. The compounds, 6g, 6h, 6i, 6k, 6l and
6m were found inactive against all bacterial strains.
3.2.2. Antifungal activity
All the compounds were also screened for antifungal potential.
Results revealed that compound 6d possessed good antifungal
activity against all the four fungal strains, speciﬁcally excellent
against A. niger strain with inhibition value of 25 mm which
was equal to the reference standard ﬂuconazole. Compound,
6f was found to exhibit good results against three fungal
strains, A. ﬂavus, G. lucidum and A. alternata but excellent
against A. ﬂavus with inhibition of 26 mm, equal to that of ref-
erence. Compounds, 6c, 6e, 6j and 6k were found to be active
against all the fungal strains but results were not appreciable.
The compounds, 6a, 6b, 6g, 6h, 6i, 6l and 6m were found inac-
tive against all fungal strains.
3.2.3. Hemolytic activity
The result of hemolytic activity (Table 4) rendered the com-
pounds 6e and 6k, the least cytotoxic because of the lowest
hemolytic activity as 5.35% and 4.61%, respectively relative
to standard triton-X with that of 100%, as positive control.
Due to lowest hemolytic activity these compounds can be
Table 4 Hemolytic activity of synthesized compounds.
Compound Hemolytic activity
(Mean)%± S.D
6a 31.46
6b 6.23
6c 21.815
6d 13.04
6e 5.35
6f 8.49
6g 7.04
6h 35.00
6i 24.07
6j 8.04
6k 4.61
6l 33.35
6m 20.05
PBS 0
Triton-X (toxicity) 100
PBS = Phosphate buffered saline.
Synthesis of 2-bromo-N-[4-(4-morpholinyl)phenyl]acetamide derivatives S433utilized in pharmacy for drug development programs. Com-
pounds, 6h and 6l were found to possess the highest cytotoxic
effect among all the synthesized compounds.
4. Conclusion
All the derivatives of 2-bromo-N-[4-(4-morpholinyl)phenyl]
acetamide were synthesized in laboratory in appreciable yields
and structure elucidation was brought about by IR, 1H-NMR,
13C-NMR and EIMS spectral data. All the synthesized deriv-
atives were screened for antibacterial activity against gram-
negative and gram-positive bacterial strains; for antifungal
potential and cytotoxic activity. The compound, 6d, possessed
the signiﬁcant results of antibacterial and antifungal activities
and that might be because of the 4-chlorophenyl group present
in the molecule. The results indicated that most of the synthe-
sized compounds have moderately good inhibitory potential
for both bacterial strains and fungal strains. Some of the deriv-
atives possess good cytotoxic potential. So these derivatives
can be considered by the pharmacists in drug development
process.
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